Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, China.
Diagn Pathol. 2014 May 29;9:100. doi: 10.1186/1746-1596-9-100.
BACKGROUND NAD(P)H: quinone oxidoreductase 1 (NQO1) plays a central role in catalyzing the two-electron reduction of quinoid compounds into hydroquinones. The NQO1 Pro187Ser polymorphism was found to correlate with a lower enzymatic activity, which may result in increased incidence of carcinomas including breast cancer. Previous studies investigating the association between NQO1 Pro187Ser polymorphism and breast cancer risk showed inconsistent results. We performed a meta-analysis to summarize the possible association.
All studies published from January 1966 to February 2014 on the association between NQO1 Pro187Ser polymorphism and breast cancer risk were identified by searching electronic databases PubMed, EMBASE, Cochrane library, and Chinese Biomedical Literature database (CBM). The association between NQO1 Pro187Ser polymorphism and breast cancer risk was assessed by odds ratios (ORs) together with their 95% confidence intervals (CIs).
Ten studies with 2,773 cases and 4,076 controls were finally included in the meta-analysis. We did not observe a significant association between NQO1 Pro187Ser polymorphism and breast cancer risk when all studies were pooled into the meta-analysis. In subgroup analysis by ethnicity, significant increased breast cancer risk was found in Caucasians (Ser/Pro vs. Pro/Pro: OR=1.145, 95% CI=1.008-1.301, P=0.038; Ser/Ser+Ser/Pro vs. Pro/Pro: OR=1.177, 95% CI=1.041-1.331, P=0.009). When stratified by source of control, significant increased breast cancer risk was found in population-based studies (Ser/Pro vs. Pro/Pro: OR=1.180, 95% CI=1.035-1.344, P=0.013; Ser/Ser+Ser/Pro vs. Pro/Pro: OR=1.191, 95% CI=1.050-1.350, P=0.007). However, in subgroup analyses according to menopausal status, quality score, and HWE in controls, no any significant association was detected.
Our meta-analysis provides the evidence that the NQO1 Pro187Ser polymorphism contributed to the breast cancer susceptibility among Caucasians. Further large and well-designed studies are needed to confirm this association.
The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1248639991252504.
背景 NAD(P)H:醌氧化还原酶 1(NQO1)在催化醌类化合物的两电子还原为氢醌方面发挥着核心作用。NQO1 Pro187Ser 多态性与较低的酶活性相关,这可能导致包括乳腺癌在内的癌症发生率增加。先前研究表明,NQO1 Pro187Ser 多态性与乳腺癌风险之间存在关联,但结果不一致。我们进行了荟萃分析以总结可能的关联。
通过检索电子数据库 PubMed、EMBASE、Cochrane 图书馆和中国生物医学文献数据库(CBM),从 1966 年 1 月至 2014 年 2 月期间,搜索了关于 NQO1 Pro187Ser 多态性与乳腺癌风险之间关联的所有研究。使用比值比(OR)及其 95%置信区间(CI)评估 NQO1 Pro187Ser 多态性与乳腺癌风险之间的关联。
最终有 10 项研究,共 2773 例病例和 4076 例对照纳入荟萃分析。当所有研究合并到荟萃分析中时,我们没有观察到 NQO1 Pro187Ser 多态性与乳腺癌风险之间存在显著关联。按种族亚组分析,在白种人中发现乳腺癌风险显著增加(Ser/Pro 与 Pro/Pro:OR=1.145,95%CI=1.008-1.301,P=0.038;Ser/Ser+Ser/Pro 与 Pro/Pro:OR=1.177,95%CI=1.041-1.331,P=0.009)。按对照来源分层,在基于人群的研究中发现乳腺癌风险显著增加(Ser/Pro 与 Pro/Pro:OR=1.180,95%CI=1.035-1.344,P=0.013;Ser/Ser+Ser/Pro 与 Pro/Pro:OR=1.191,95%CI=1.050-1.350,P=0.007)。然而,按绝经状态、质量评分和对照人群中的 HWE 进行亚组分析时,未发现任何显著关联。
本荟萃分析提供的证据表明,NQO1 Pro187Ser 多态性与白种人乳腺癌易感性相关。需要进一步进行大型和精心设计的研究来证实这种关联。